Clinical trials
Liver Neoplasms trials in Belgium
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
30 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 2 |
| 2002 | 1 |
| 2005 | 1 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 4 |
| 2018 | 3 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 17 |
| Terminated | 6 |
| Recruiting | 3 |
| Active, not recruiting | 2 |
| Enrolling by invitation | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bayer | 4 |
| Bristol-Myers Squibb | 3 |
| Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 2 |
| European Hepatocellular Cancer Liver Transplant Group | 2 |
| Abbott | 1 |
| AstraZeneca | 1 |
| BTG International Inc. | 1 |
| Basilea Pharmaceutica | 1 |
| Eli Lilly and Company | 1 |
| Erasmus Medical Center | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Liver Neoplasms | 30 |
| Carcinoma, Hepatocellular | 15 |
| Neoplasms | 6 |
| Bile Duct Neoplasms | 2 |
| Cholangiocarcinoma | 2 |
| Esophageal Neoplasms | 2 |
| Lung Neoplasms | 2 |
| Ovarian Neoplasms | 2 |
| Pancreatic Neoplasms | 2 |
| Adenocarcinoma | 1 |
Trials
Showing 26 to 30 of 30. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.